Company news · 2025-01-15

RCMT advances Tvac001 clinical preparation for solid tumors

The team is accelerating clinical preparation for Tvac001, an individualized neoantigen vaccine approach for advanced solid tumors.

Full press materials may be published on partner channels or the China website.